Key statistics
As of last trade Cytodyn Inc (296:BER) traded at 0.00, -100.00% above its 52-week low of 0.12, set on Nov 29, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.00 |
---|---|
High | 0.00 |
Low | 0.00 |
Bid | -- |
Offer | -- |
Previous close | 0.00 |
Average volume | -- |
---|---|
Shares outstanding | 1.21bn |
Free float | 1.21bn |
P/E (TTM) | -- |
Market cap | 187.48m USD |
EPS (TTM) | -0.0527 USD |
Data delayed at least 15 minutes, as of Dec 20 2023 08:52 GMT.
More ▼
Announcements
- CytoDyn Appoints Dr. Max Lataillade as Senior Vice President and Head of Clinical Development
- CytoDyn Announces Abstract that Highlights Leronlimab’s Potential in Mediating ART-Free Viral Control in Infant Rhesus Macaques
- CytoDyn Engages Syneos Health as CRO For Its Phase II Oncology Trial
- CytoDyn Announces Preliminary Findings in Study with SMC Laboratories
- September 2024 Letter to Shareholders
- CytoDyn Engages Leading CRO For Phase II Inflammation Trial
- CytoDyn Announces Completion of FDA Meeting on Phase II Study of Leronlimab in Patients with Relapsed/Refractory Microsatellite Stable Colorectal Cancer
- CytoDyn Announces Settlement with Amarex Clinical Research LLC
- CytoDyn Announces Start of Preclinical MASH Study, Results Expected in Fall 2024
- CytoDyn to Host Webcast to Provide Company Update
More ▼